KR970701551A - 리포좀 제제(liposome preparation) - Google Patents
리포좀 제제(liposome preparation)Info
- Publication number
- KR970701551A KR970701551A KR1019960704935A KR19960704935A KR970701551A KR 970701551 A KR970701551 A KR 970701551A KR 1019960704935 A KR1019960704935 A KR 1019960704935A KR 19960704935 A KR19960704935 A KR 19960704935A KR 970701551 A KR970701551 A KR 970701551A
- Authority
- KR
- South Korea
- Prior art keywords
- liposome
- liposome preparation
- compound
- preparation according
- group
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract 45
- 238000002360 preparation method Methods 0.000 title claims abstract 30
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 150000002632 lipids Chemical class 0.000 claims abstract 10
- 239000012528 membrane Substances 0.000 claims abstract 10
- -1 2'-deoxycytidine compound Chemical class 0.000 claims abstract 8
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 claims abstract 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 9
- 150000003904 phospholipids Chemical class 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 7
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical group CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 5
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 4
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 claims 4
- 235000012000 cholesterol Nutrition 0.000 claims 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 4
- GFFXZLZWLOBBLO-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=CF)[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-BWVDBABLSA-N 0.000 claims 2
- PULHLIOPJXPGJN-BWVDBABLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 PULHLIOPJXPGJN-BWVDBABLSA-N 0.000 claims 2
- FIGGQGCOJFHEJY-CDNBRZBRSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;dihydrate Chemical compound O.O.O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 FIGGQGCOJFHEJY-CDNBRZBRSA-N 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 claims 1
- XTYUGPDATYNDMJ-YPMAUOMFSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one;dihydrate Chemical compound O.O.O=C1N=C(N)C=CN1[C@H]1C(=C)[C@H](O)[C@@H](CO)O1 XTYUGPDATYNDMJ-YPMAUOMFSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- 102000002322 Egg Proteins Human genes 0.000 claims 1
- 108010000912 Egg Proteins Proteins 0.000 claims 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 claims 1
- 235000013345 egg yolk Nutrition 0.000 claims 1
- 210000002969 egg yolk Anatomy 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001519 tissue Anatomy 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 리포좀내에 피포된 수용성 2'-데옥시사이티딘 화합물 및 지질막 표면을 양으로 하전시키는 화합물을 함유하는 리포좀 제제에 관한 것이다. 이 제제는 악성종향 저항성을 가지는 상기 화합물의 골수조직에 대한 독성을 감소시키는 것 뿐만 아니라, 혈중에서의 향상된 체류능력에 의해 종양 조직에서 활성성분이 집적되는 것 또한 예견되며, 이 제제는 부착용을 초래하지 않고도, 항종양효과를 유지하거나 향상시킬 수 있고, 악성종양의 치료에 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 1의 결과를 나타낸다,
제2도는 실험에 2의 결과를 나타낸다,
제3도는 실시예 3의 결과를 나타낸다,
제4도는 실험예 4의 결과를 나타낸다,
제5도는 실험예 5의 결과를 나타낸다.
Claims (25)
- 리포좀내에 피포된 수용성 2'-데옥시사이티딘 화합물 및 지질막 표면을 양으로 하전시키는 화합물을 함유하는 것을 특징으로 하는 리포좀 제제.
- 리포좀내에 피포된 수용성 2'-데옥시사이티딘 화합물, 안정화제 및 지질막 표면을 양으로 하전시키는 화합물을 함유하는 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 2'-데옥시사이티딘 화합물을 2'-데옥시-2'-메틸리덴사이티딘, 2'-데옥시-2'-플루오로메틸리덴사이티딘, 2'-데옥시-2'-메틸리덴-5-플루오로사이티딘, 2'-데옥시-2',2'-디플루오로사이티딘 및 2'-C-시아노-2'-데옥시-β-아라비노프라노실사이토신, 및 이들의 약제학적으로 허용가능한 염과 수화물로 이루어진 군으로부터 선택함을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 2'-데옥시사이티딘 화합물을 2'-데옥시-2'-메틸리덴사이티딘, 2'-데옥시-2'-플루오로메틸리덴사이티딘, 2'-데옥시-2'-메틸리덴-5-플루오로사이티딘, 및 이들의 약제학적으로 허용가능한 염과 수화물로 이루어진 군으로부터 선택함을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 2'-데옥시사이티딘 화합물이 2'-데옥시-2'-메틸리덴사이티딘 이수화물인 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 지질막 표면을 양으로 하전시키는 화합물을 스테아릴아민, 올레일아민, 스핑고신, 포스파티딜에탄올아민, N-[1-(2,3-디올레일옥시)프로필]-N,N,N-트리메틸암모늄 염화물, 콜레스테릴헤미숙시네이트, 3B-[N-(N',N'-디메틸아미노에탄)카바모일]콜레스테롤 및 콜레스테릴(4'-트리메틸암모니오)부타노에이트로 이루어진 군으로부터 선택함을 특징으로 하는 리포좀 제제.
- 제1항 도는 제2항에 있어서, 지질막 표면을 양으로 하전시키는 화합물을 스테아릴아민과 스핑고신으로 이루어진 군으로부터 선택함을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 지질막 표면을 양으로 하전시키는 화합물이 스테아릴아민인 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 지질막 표면을 양으로 하전시키는 화합물이 스핑고신인 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀이 37℃ 이상의 겔-액체 상전이 온도를 갖는 인지질로 구성된 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀이 40~65℃의 겔-액체 상전이 온도를 갖는 인지질로 구성된 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀이 수소화 정제 난황 포스파티딜콜린, 수소화 정제 콩 포스파티딜콜린, 디팔미토일포스파티딜콜린 및 디스테아로인포스파티딜콜린으로 이루어진 군으로부터 선택된 인지질로 구성된 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀이 수소화 정제 콩 포스파티딜콜린 및 디팔미토일포스파티딜콜린으로 이루어진 군으로부터 선택된 인지질로 구성된 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀이 수소화 정제 콩 포스파티딜콜린으로 구성된 것을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 안정화제를 스테롤류 및 스핑고마이엘린으로 이루어진 군으로부터 선택함을 특징으로 하는 리포좀 제제.
- 제2항에 있어서, 안정화제를 스테롤류로 이루어진 군으로부터 선택함을 특징으로 하는 리포좀 제제.
- 제2항에 있어서, 안정화제가 콜레스테롤임을 특징으로 하는 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀의 평균입자 크기가 50~200nm인 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀의 평균입자 크기가 100~180nm인 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀의 평균입자 크기가 120~160nm인 리포좀 제제.
- 제1항 또는 제2항에 있어서, 리포좀의 평균입자 크기가 150~160nm인 리포좀 제제.
- 제2항에 있어서, 인지질 1몰당 지질막 표면을 양으로 하전시키는 화합물을 0.001~0.4몰 및 안정화제를 0.6~1몰 함유하는 리포좀 제제.
- 제2항에 있어서, 인지질 1몰당 지질막 표면을 양으로 하전시키는 화합물을 0.02~0.4몰 및 안정화제를 0.6~1몰 함유하는 리포좀 제제.
- 리포좀내에 피포된 수용성 2'-데옥시사이티딘 이수화물 및 지질막 표면은 양으로 하전되었고, 수소화 정제 콩 포스파티딜콜린과 디팔미토일포스파티딜콜린으로 이루어진 군으부터 선택된 인지질 1몰당 0.001~0.4몰의 스테아릴아민 또는 스핑고신 및 0.6~1몰의 콜레스테롤로 구성되며, 평균입자크기가 50~200nm인 리포좀으로 이루어진 것을 특징으로 하는 리포좀 제제.
- 리포좀내에 피포된 수용성 2'-데옥시사이티딘 이수화물 및 지질막 표면은 양으로 하전되었고, 리포좀은 수소화 정제 콩 포스파티딜콜린과 디팔미토일포스파티딜콜린으로 이루어진 군으부터 선택된 인지질 1몰당 0.02~0.4몰의 스테아릴아민 또는 스핑고신 및 0.6~1몰의 콜레스테롤로 구성되며, 평균입자크기가 120~160nm인 리포좀으로 이루어진 것을 특징으로 하는 리포좀 제제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4106594 | 1994-03-11 | ||
| JP94-41065 | 1994-03-11 | ||
| PCT/JP1995/000383 WO1995024201A1 (fr) | 1994-03-11 | 1995-03-08 | Preparation de liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970701551A true KR970701551A (ko) | 1997-04-12 |
Family
ID=12598041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960704935A KR970701551A (ko) | 1994-03-11 | 1995-03-08 | 리포좀 제제(liposome preparation) |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5776488A (ko) |
| EP (1) | EP0750910A4 (ko) |
| KR (1) | KR970701551A (ko) |
| CA (1) | CA2184834A1 (ko) |
| WO (1) | WO1995024201A1 (ko) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010003580A1 (en) * | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| EP1044679B1 (en) * | 1998-11-02 | 2012-12-26 | Terumo Kabushiki Kaisha | Stable Liposomes for Targeted Drug Delivery |
| WO2000048611A1 (fr) * | 1999-02-18 | 2000-08-24 | Sankyo Company, Limited | Preparations de liposomes contenant des medicaments antitumoraux |
| CA2382821A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| IT1315253B1 (it) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| WO2002032396A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for delivery of nucleic acids |
| WO2003075890A1 (en) * | 2002-03-05 | 2003-09-18 | Transave, Inc. | Methods for entrapment of bioactive agent in a liposome or lipid complex |
| AU2003268087A1 (en) * | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
| MXPA05008284A (es) | 2003-02-03 | 2006-03-21 | Neopharm Inc | Taxano y otros farmacos antineoplasicos encapsulados, liposomicos, estables, susceptibles de esterilizacion por filtracion. |
| WO2005020935A2 (en) * | 2003-02-06 | 2005-03-10 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Method and composition of administering radioprotectants |
| EA200501285A1 (ru) * | 2003-02-11 | 2006-02-24 | Неофарм, Инк. | Способ получения липосомальных препаратов |
| JP4617458B2 (ja) * | 2004-02-10 | 2011-01-26 | 財団法人ヒューマンサイエンス振興財団 | 中空糸透析カラムを利用したリポソームの製造方法 |
| WO2006032136A1 (en) * | 2004-09-20 | 2006-03-30 | British Columbia Cancer Agency Branch | Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin |
| WO2007044748A2 (en) * | 2005-10-11 | 2007-04-19 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| TWI428135B (zh) * | 2007-03-26 | 2014-03-01 | Hirofumi Takeuchi | And a carrier composition for quick-acting nucleic acid delivery |
| JP5532921B2 (ja) * | 2007-05-14 | 2014-06-25 | コニカミノルタ株式会社 | リポソーム |
| EP2165694B8 (en) * | 2007-05-29 | 2017-11-08 | Pola Chemical Industries Inc. | Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle |
| TWI468188B (zh) | 2008-01-30 | 2015-01-11 | Univ Tokushima | Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation |
| US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
| WO2010074172A1 (ja) * | 2008-12-24 | 2010-07-01 | 株式会社バイオメッドコア | リポソームの製造方法ならびにコレステロール溶解方法 |
| JP5771366B2 (ja) | 2009-09-02 | 2015-08-26 | 株式会社バイオメッドコア | リポソーム製造装置及び方法 |
| US9162014B2 (en) * | 2010-01-25 | 2015-10-20 | Concept Medical Research Private Limited | Method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent |
| US8912162B2 (en) * | 2010-07-13 | 2014-12-16 | Clavis Pharma Asa | Parenteral formulations of elacytarabine derivatives |
| PL226015B1 (pl) * | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposomowy preparat zawierajacy przeciwnowotworowa substancje aktywna, sposob jego wytwarzania i zawierajaca go kompozycja farmaceutyczna |
| JP5882108B2 (ja) * | 2011-03-31 | 2016-03-09 | 花王株式会社 | ベシクル組成物 |
| US20140161876A1 (en) * | 2011-07-15 | 2014-06-12 | Konica Minolta, Inc. | Liposome-containing preparation utilizing dissolution aid, and method for producing same |
| US9408846B2 (en) * | 2012-04-23 | 2016-08-09 | The Children's Medical Center Corporation | Formulations and methods for delaying onset of chronic neuropathic pain |
| SG10201701063WA (en) | 2012-08-10 | 2017-04-27 | Taiho Pharmaceutical Co Ltd | Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same |
| EP3240579B1 (en) | 2014-12-31 | 2022-07-27 | Lantheus Medical Imaging, Inc. | Lipid-encapsulated gas microsphere compositions and related methods |
| JP6884783B2 (ja) * | 2015-12-08 | 2021-06-09 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. | リポソームの製造方法 |
| TWI832081B (zh) | 2016-05-04 | 2024-02-11 | 美商藍瑟斯醫學影像公司 | 用於形成充氣微球體及成像個體之方法、震盪裝置及電腦可讀軟體 |
| US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5246708A (en) * | 1987-10-28 | 1993-09-21 | Pro-Neuron, Inc. | Methods for promoting wound healing with deoxyribonucleosides |
-
1995
- 1995-03-08 CA CA002184834A patent/CA2184834A1/en not_active Abandoned
- 1995-03-08 WO PCT/JP1995/000383 patent/WO1995024201A1/ja not_active Application Discontinuation
- 1995-03-08 KR KR1019960704935A patent/KR970701551A/ko not_active Application Discontinuation
- 1995-03-08 EP EP95910773A patent/EP0750910A4/en not_active Withdrawn
- 1995-03-08 US US08/716,201 patent/US5776488A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5776488A (en) | 1998-07-07 |
| EP0750910A1 (en) | 1997-01-02 |
| WO1995024201A1 (fr) | 1995-09-14 |
| EP0750910A4 (en) | 1997-07-09 |
| CA2184834A1 (en) | 1995-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970701551A (ko) | 리포좀 제제(liposome preparation) | |
| US5200393A (en) | Lipid excipient for nasal delivery and topical application | |
| US4755388A (en) | Liposome-encapsulated 5-fluoropyrimidines and methods for their use | |
| AU2002305094C1 (en) | Liposome composition for improved intracellular delivery of a therapeutic agent | |
| US4804539A (en) | Ophthalmic liposomes | |
| CA2196780A1 (en) | A liposomal delivery system comprising cationic lipopolyamines and neutral lipids for delivery of biologically active agents | |
| DE69207603T2 (de) | Zusammensetzung und verfahren zur behandlung von zystischer fibrose | |
| CA1237670A (en) | Drug preparations of reduced toxicity | |
| KR890014097A (ko) | 리포좀 조성물 | |
| CA2427467A1 (en) | Sn-38 lipid complexes and methods of use | |
| CA2335250A1 (en) | Temperature-sensitive liposomal formulation | |
| CA2236918A1 (en) | Topical compositions for regulating the oily/shiny appearance of skin | |
| AU2002305094A1 (en) | Liposome composition for improved intracellular delivery of a therapeutic agent | |
| BRPI0413889A (pt) | formulação lipossÈmica farmacêutica | |
| BR0117197A (pt) | Formulação de medicamento contendo ciclosporina aplicação do mesmo | |
| JP3383704B2 (ja) | 安定なリポソーム水分散液 | |
| WO1990012565A1 (en) | Water-containing formulations with phospholipids | |
| Maekawa et al. | Selective treatment of metastatic lymph nodes with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin | |
| JP2807840B2 (ja) | リポソーム及びリン脂質分散液の安定化法 | |
| KR101154442B1 (ko) | 배당체 함유 리포솜 | |
| ITMI942166A1 (it) | Composizioni farmaceutiche miorilassanti | |
| CA2524179A1 (en) | A composition and its use for adminstration of mitomycin c in vivo for treating a multi-drug resistant tumor | |
| CA2211409A1 (en) | Novel pharmaceutical formulation | |
| CA2093133A1 (en) | Synthetic lung surfactant | |
| HUP0203473A2 (hu) | 6,9-Bisz-[(2-aminoetil)amino]benzo[g]izokinolin-5,10-dion-dimaleát liposzómás készítmény |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |